Confirms Annual Filings on SEDAR
CALGARY, Alberta, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces that it has filed its annual financial statements for the year ended April 30, 2020 and related management's discussion and analysis pursuant to National Instrument 51-102 (collectively, the "Annual Filings"). The Company had previously relied on exemptive relief issued by provincial securities commissions – due to the COVID-19 outbreak – to extend the date of filing of its Annual Filings for the year ended April 30, 2020. These filings can be found at www.sedar.com under the Company’s profile.
Further to its October 1, 2020 press release, the Company continues to expect to file its interim financial statements and related management's discussion and analysis for the three months ended July 31, 2020 (collectively, the "Interim Filings") on or about October 30, 2020.
Zenith also confirms there have been no undisclosed material business developments, since its news release on October 1, 2020 regarding the status of its continuous disclosure filings, that have not been otherwise disclosed by Zenith by way of news release.
Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for:
- Metastatic Castration Resistant Prostate Cancer (“mCRPC”) in combination with androgen receptor inhibitor, XTANDI
- Triple Negative Breast Cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator
- Androgen receptor independent mCRPC in combination with immune checkpoint inhibitor Keytruda and XTANDI
For further information, please contact:
Investor Relations & Communications
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the anticipated timeline for filing continuous disclosure documents. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.